EA
EPZM

Emerald Acquisition’s Epizyme, Inc EPZM Stock Holding History

Emerald Acquisition’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		$44K Hold
4,500
– – ﹤0.01% 2895
2016
Q2 		$46K Buy
+4,500
New +$50.2K ﹤0.01% 2923

Other funds holding EPZM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Emerald Acquisition's EPZM Position: Q3 2016 in Review

Emerald Acquisition held its Epizyme, Inc (EPZM) position steady in Q3 2016 at 4,500 shares worth $44K. The position accounts for ﹤0.01% of the portfolio, ranked #2895.

Emerald Acquisition first reported a position in EPZM in Q2 2016 and has held it in 2 quarters since. The position peaked at $46K in Q2 2016. 97 funds tracked by Wall St. Rank hold EPZM as of Q3 2016.

  • Emerald Acquisition held 4,500 shares of Epizyme, Inc worth $44K as of Q3 2016.
  • Emerald Acquisition left its Epizyme, Inc share count unchanged in Q3 2016.
  • Epizyme, Inc made up ﹤0.01% of Emerald Acquisition's portfolio in Q3 2016, its #2895 holding.
  • Emerald Acquisition first reported a position in Epizyme, Inc in Q2 2016 and has held it in 2 quarters since.
  • Emerald Acquisition's Epizyme, Inc position peaked at $46K in Q2 2016.
  • 97 funds tracked by Wall St. Rank held Epizyme, Inc as of Q3 2016.

Based on Emerald Acquisition's 13F filing for Q3 2016, filed 9 Nov 2016.